FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 404 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Neoadjuvant Pembrolizumab Combined with Chemotherapy Followed by Adjuvant Pembrolizumab Significantly Improves... February 15, 2022 Jiffy Lube Surprises Volunteer Who Drives Cancer Patients To Treatment With... December 11, 2019 ESMO Asia Virtual Congress 2020, 20-22 November October 26, 2020 Hospital Lockdown Prevents Breast Cancer Patient from Receiving Treatment for 3... May 17, 2021 Load more HOT NEWS Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab... ESMO Welcomes New Cancer Focused UN Political Declaration on Non-Communicable Diseases New on NCI’s Websites for June 2020 Feasibility and Safety of Preoperative Treatment with Nivolumab and Relatlimab in...
